Akèy › Kansè Poumon ki pa ti selil › Georgia › Atlanta
Etid klinik pou Kansè Poumon ki pa ti selil nan Atlanta, GA
47 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Atlanta (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Northside Hospital, Atlanta
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Winship Cancer Institute of Emory University, Atlanta
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Emory University, Atlanta
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
- ak 1 plis
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Emory Winship Cancer Institute, Atlanta
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- Winship Cancer Institute of Emory University, Atlanta
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Piedmont Healthcare, Inc, Atlanta
- Winship Cancer Institute, Atlanta
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- Piedmont Atlanta Hospital ( Site 4000), Atlanta
- Emory University School of Medicine-Phase I ( Site 0056), Atlanta
- Northside Hospital ( Site 0055), Atlanta
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Emory University Winship Cancer Institute, Atlanta
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Grady Health System Correll Pavilion, Atlanta
- Piedmont Healthcare, Atlanta
- Piedmont Cancer Institute, Atlanta
- ak 1 plis
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Winship Cancer Institute, Atlanta
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Piedmont Cancer Institute, Atlanta
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Atlanta
- Research Site, Atlanta
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1
- Emory Winship Cancer Institute, Atlanta
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- Piedmont Healthcare, Atlanta
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Ap rekriteFaz 1/2
- Winship Cancer Institute at Emory University, Atlanta
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Atlanta
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Ap rekriteFaz 3
- Piedmont Cancer Institute, Atlanta
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Piedmont Cancer Institute OneOncology, Atlanta
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Emory University, Atlanta
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Piedmont Cancer Institute, PC, Atlanta
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Emory University School of Medicine- Grady Campus, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Piedmont Cancer Institute, PC, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- Emory University, Atlanta
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Ap rekriteFaz 1/2
- Emory University, Atlanta
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Emory Winship Cancer Institute, Atlanta
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Emory University School of Medicine, Atlanta
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Emory University, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Ap rekriteFaz 1/2
- Winship Cancer Institute - Emory University, Atlanta
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Ap rekriteFaz 3
- Emory University - Winship Cancer Institute, Atlanta
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Research Site, Atlanta
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- Winship Cancer Institute, Atlanta
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Northside Hospital, Atlanta
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA10-0, Atlanta
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Ap rekriteFaz 1
- Winship Cancer Institute at Emory University, Atlanta
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Piedmont Healthcare, Atlanta
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- ak 3 plis
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 111, Atlanta
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Emory University Hospital/Winship Cancer Institute, Atlanta
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Northside Hospital, Atlanta
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Ap rekriteFaz 1 bonè
- Emory University/Winship Cancer Institute, Atlanta
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Ap rekriteFaz 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- Morehouse School of Medicine (MSM), Atlanta
- Piedmont Healthcare, Atlanta
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 114, Atlanta
- Research Site 139, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Atlanta
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Atlanta
- Kansè (tout kalite)49 etid
- Myelom Miltip42 etid
- Kansè nan tete41 etid
- Kansè pwostat33 etid
- Leksemi mieloïd egi31 etid
- Kansè ovè29 etid
- Kansè kolorektal29 etid
- Kansè poumon29 etid
- Kansè Metastatik28 etid
- Twoub depresif majè25 etid
- Ensifizyans kadyak25 etid
- Karsinòm selil skuamèz tèt ak kou24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.